Novavax, Inc. (NVAX) Financial Statements
Novavax, Inc. (NVAX) reported trailing twelve-month revenue of $413.8M (down 61.6% year on year) and net income of -$247.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$43.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NVAXNovavax, Inc.Follow NVAX — free
—
Price chart with a free account
- Market cap
- 1.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.02 | 0.02 | 0.03 | 0.04 | 0.02 | 0.03 | 0.03 | 0.02 | 0.48 | 1.15 | 1.98 | 0.98 | 0.68 | 1.12 | 0.41 | |
| Gross profit | — | — | — | — | — | — | — | — | — | — | 1.08 | 0.64 | 0.48 | 1.05 | 0.33 | |
| Research & development | 0.03 | 0.06 | 0.09 | 0.16 | 0.24 | 0.17 | 0.17 | 0.11 | 0.75 | 2.53 | 1.24 | 0.74 | 0.39 | 0.34 | 0.34 | |
| Operating income | -0.03 | -0.05 | -0.08 | -0.16 | -0.27 | -0.17 | -0.17 | -0.12 | -0.42 | -1.69 | -0.64 | -0.57 | -0.25 | 0.45 | -0.23 | |
| Pre-tax income | -0.03 | -0.05 | -0.08 | -0.16 | — | — | — | -0.13 | -0.42 | -1.71 | -0.65 | -0.54 | -0.18 | 0.44 | -0.25 | |
| Income tax | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | |
| Net income | -0.03 | -0.05 | -0.08 | -0.16 | -0.28 | -0.18 | -0.18 | -0.13 | -0.42 | -1.74 | -0.66 | -0.55 | -0.19 | 0.44 | -0.25 | |
| Diluted EPS ($) | -0.22 | -0.31 | -0.37 | -0.60 | -1.03 | -12.56 | -9.99 | -5.51 | -7.27 | -23.44 | -8.42 | -5.41 | -1.23 | 2.58 | -1.58 | |
| Diluted shares (bn) | — | — | — | — | — | — | — | — | — | 0.074 | 0.078 | 0.101 | 0.152 | 0.173 | — |
USD billions · SEC XBRL
Novavax, Inc. — questions
- What is Novavax, Inc.'s revenue?
- $413.8M over the twelve months to 2026-06-30, down 61.6% year on year, from its 10-Q and 10-K filings.
- What is Novavax, Inc.'s net income?
- -$247.7M over the twelve months to 2026-06-30.
- What is Novavax, Inc.'s free cash flow?
- -$43.0M over the twelve months to 2026-06-30.
- What are Novavax, Inc.'s diluted earnings per share?
- $-1.58 over the twelve months to 2026-06-30.
Every figure on this page comes from Novavax, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.